决奈达隆及其活性代谢物PBPK模型构建与验证:预测与利伐沙班复杂药物相互作用
本研究采用中通量方法构建并验证决奈达隆及其活性代谢物NDBD的PBPK模型,并用辛伐他汀和地高辛验证CYP3A4和P-gp介导的DDI预测能力。模型预测健康及轻度肾损伤人群中决奈达隆与利伐沙班联用可使利伐沙班AUC0-24h分别增加1.65倍和1.84倍,轻度肾损伤者大出血风险4.70%超过4.5%阈值,建议利伐沙班减量至至少15 mg。
要点
- 决奈达隆与利伐沙班联用预测可显著增加利伐沙班暴露,健康人AUC0-24h增1.65倍,轻度肾损伤者增1.84倍。
- 轻度肾损伤患者联用时预测大出血风险4.70%,超过代表禁忌联用的4.5%阈值。
- 轻度肾损伤患者联用决奈达隆时,利伐沙班剂量应至少减至15 mg以改善获益风险比。
核心结论
- PBPK-DDI模型预测决奈达隆与利伐沙班在健康及轻度肾损伤受试者中均存在有临床意义的药物相互作用。
研究设计与样本
- 采用中通量方法构建决奈达隆及其主要代谢物NDBD的PBPK模型,整合文献或内部体外数据、计算机预测数据和体内临床数据。
- 对静脉及口服(单次和多次)给药方案进行模型验证,并以辛伐他汀和地高辛分别验证CYP3A4和P-gp介导的DDI预测准确性。
- 将决奈达隆和/或NDBD对CYP3A4、CYP2J2、OAT3和P-gp的抑制参数纳入PBPK-DDI模型,前瞻性模拟健康及轻度肾损伤人群的决奈达隆-利伐沙班DDI。
主要发现
- 纳入自身灭活对剂量非线性影响后,模型准确模拟了临床相关剂量400 mg决奈达隆单次和多次口服后决奈达隆及NDBD的药代动力学。
- 未剂量调整的利伐沙班-决奈达隆DDI模拟中,健康人群利伐沙班AUC0-24h倍数变化为1.65,轻度肾损伤人群为1.84,均超过剂量暴露等效范围0.70-1.43。
- 相应预测大出血风险分别为4.24%和4.70%,对照阈值4.5%代表利伐沙班-酮康唑禁忌DDI。
关键数值与推荐
- 利伐沙班AUC0-24h剂量暴露等效范围为0.70-1.43。
- 大出血风险阈值4.5%代表利伐沙班-酮康唑禁忌DDI。
- 轻度肾损伤受试者联用决奈达隆和利伐沙班时,利伐沙班剂量应至少减至15 mg。
临床怎么用
- 临床对房颤患者联用决奈达隆与利伐沙班时应警惕利伐沙班暴露增加及出血风险。
- 轻度肾损伤患者同时使用决奈达隆和利伐沙班时,建议将利伐沙班剂量至少减至15 mg。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Despite potential enzyme- and transporter-mediated drug-drug interactions (DDIs) between dronedarone and rivaroxaban in atrial fibrillation (AF) patients, pharmacokinetic/pharmacodynamic data remain limited to guide clinical practice. We aimed to develop, verify and validate a physiologically based pharmacokinetic (PBPK) model of dronedarone and its major metabolite, N-desbutyldronedarone (NDBD), to prospectively interrogate this clinically relevant DDI in healthy and mild renal impairment populations. METHODS: The middle-out development of our PBPK model combined literature-derived or in-house in vitro data, predicted in silico data and in vivo clinical data. Model verification was performed for intravenous and oral (single and multiple) dosing regimens. Model validation for the accurate prediction of cytochrome P450 (CYP)3A4- and P-glycoprotein-mediated DDI utilized simvastatin and digoxin as respective victim drugs. Rivaroxaban-specific inhibitory parameters of dronedarone and/or NDBD against CYP3A4, CYP2J2, OAT3 and P-glycoprotein were incorporated into the PBPK-DDI model for prospective dronedarone-rivaroxaban DDI simulation. RESULTS: Dronedarone and NDBD PK following clinically relevant doses of 400 mg dronedarone across single and multiple oral dosing were accurately simulated by incorporating effect of auto-inactivation on dose nonlinearities. Following successful model validation, nondose-adjusted rivaroxaban-dronedarone DDI in healthy and mild renal impairment populations revealed simulated rivaroxaban area under the plasma concentration-time curve up to 24 h fold change greater than dose exposure equivalence (0.70-1.43) at 1.65 and 1.84, respectively. Correspondingly, respective major bleeding risk was 4.24 and 4.70% compared with threshold of 4.5% representing contraindicated rivaroxaban-ketoconazole DDI. CONCLUSION: Our PBPK-DDI model predicted clinically significant dronedarone-rivaroxaban DDI in both healthy and mild renal impairment subjects. Greater benefit vs. risk could be achieved with rivaroxaban dose reductions to at least 15 mg in mild renal impairment subjects on concomitant dronedarone and rivaroxaban.
引用
- Leow JWH, Ang XJ, Chan ECY, et al. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban. Br J Clin Pharmacol. 2023. PMID: 36683488. doi:10.1111/bcp.15670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。